06 October 2025 | Monday | News
KARL STORZ, a global leader in minimally invasive surgical technology, is proud to announce it has received U.S. Food and Drug Administration (FDA) clearance for the ENDOFLATOR™ +.
ENDOFLATOR + is the next-generation insufflator with integrated surgical smoke evacuation system designed to meet the evolving needs of modern operating rooms.
Using carbon dioxide gas, an insufflator establishes and maintains a stable working cavity within the body during laparoscopic and robotic procedures, providing surgeons with the necessary space to operate. When paired with smoke evacuation, the insufflator is designed to preserve image clarity by removing surgical smoke and particulates, improving visibility and allowing for enhanced surgical precision.
The ENDOFLATOR + represents a significant leap forward, offering high flowrates and an ULPA filter that helps maintain a smoke-free image, improving visibility and maneuverability while reducing harmful surgical smoke. Specific features include:
The system is engineered to support procedures across various specialties—general surgery, cardiovascular surgery, colorectal surgery, gynecology, pediatric surgery*, proctology, and urology—in both conventional laparoscopic and robotic settings.
“This launch marks a major milestone for KARL STORZ and the healthcare providers we serve,” said Fernando Morales, Vice President, Surgical & OR Integration. “The ENDOFLATOR + not only meets high standards of safety and performance but also aligns with new surgical smoke evacuation mandates across multiple states.”
The ENDOFLATOR + and its five proprietary tubing sets are now available for order. Customers are encouraged to contact their KARL STORZ representative for demos, pricing, and promotional offers.
*cleared for patients aged 2 and up
© 2025 Biopharma Boardroom. All Rights Reserved.